MedElevator
Войти в исследования Neurology(R) neuroimmunology & neuroinflammation · 2025
Amaurosis Fugax Dolorosa: A Prodromal Syndrome in Optic Neuritis Associated With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Vilaseca Andreu, Syc-Mazurek Stephanie B, Vorasoot Nisa, Tajfirouz Deena A, Eggenberger Eric, Chodnicki Kevin D, Pittock Sean J, Chen John J, Flanagan Eoin P
Аннотация
OBJECTIVES: Amaurosis fugax (AF) is typically vascular but can rarely be associated with optic neuritis (ON). We describe AF preceding myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) ON.
METHODS: We retrospectively reviewed our MOGAD cohort (July 2024-April 2024). Inclusion criteria were (1) AF-defined as transient visual loss <24 hours without retinal ischemic lesions-before first ON and (2) fulfilled international MOGAD 2023 diagnostic criteria. Demographics, symptoms/signs, MRI, and optical coherence tomography (OCT) data were collected. Descriptive statistics summarized the findings.
RESULTS: In total, 8 of 350 (2.3%) MOGAD patients with ON experienced AF. Most patients (7/8, 87.5%) were women, and all reported periocular pain. Transient visual episodes were typically brief (median, 15 minutes; range, 1-300 minutes) and usually less than 1 hour (6/8, 75.0%). Amaurosis fugax affected the right (n = 4), left (n = 3), or both (n = 1) eyes. Within 1 week, 7 developed ON. MRI showed optic nerve enhancement in involved eye in 8 of 8 (100%). OCT completed in 1 patient at the time of AF showed increased peripapillary retinal nerve fiber layer thickness. No alternative diagnoses emerged during follow-up.
DISCUSSION: Painful AF is a previously unrecognized and specific prodrome of MOGAD-associated ON; identifying this rare presentation may enable earlier diagnosis and treatment.
METHODS: We retrospectively reviewed our MOGAD cohort (July 2024-April 2024). Inclusion criteria were (1) AF-defined as transient visual loss <24 hours without retinal ischemic lesions-before first ON and (2) fulfilled international MOGAD 2023 diagnostic criteria. Demographics, symptoms/signs, MRI, and optical coherence tomography (OCT) data were collected. Descriptive statistics summarized the findings.
RESULTS: In total, 8 of 350 (2.3%) MOGAD patients with ON experienced AF. Most patients (7/8, 87.5%) were women, and all reported periocular pain. Transient visual episodes were typically brief (median, 15 minutes; range, 1-300 minutes) and usually less than 1 hour (6/8, 75.0%). Amaurosis fugax affected the right (n = 4), left (n = 3), or both (n = 1) eyes. Within 1 week, 7 developed ON. MRI showed optic nerve enhancement in involved eye in 8 of 8 (100%). OCT completed in 1 patient at the time of AF showed increased peripapillary retinal nerve fiber layer thickness. No alternative diagnoses emerged during follow-up.
DISCUSSION: Painful AF is a previously unrecognized and specific prodrome of MOGAD-associated ON; identifying this rare presentation may enable earlier diagnosis and treatment.